京万红软膏上调PDGF mRNA表达改善大鼠缺血合并外伤型糖尿病足的研究

目的考察京万红软膏对大鼠缺血合并外伤型糖尿病足的疗效及作用机制。方法建立糖尿病大鼠模型,在此基础上建立大鼠缺血合并外伤型糖尿病足模型。实验设置4组,每组大鼠15只,分别为假手术组、模型组、京万红软膏组、重组人表皮生长因子外用溶液(rhEGF)组。给药14 d,记录给药前后大鼠体质量、血糖、足部形态及溃疡面积的变化情况。并于给药后取足部溃疡部位组织行HE染色,采用RT-PCR法检测京万红软膏对血小板源性生长因子(PDGF)、血管内皮生长因子(VEGF)及其受体FLT-1 mRNA表达的影响。结果京万红软膏对大鼠缺血合并外伤型糖尿病足具有消肿生肌,促进创面愈合的功效。与模型组相比,京万红软膏组给药14 d后可极显著减少大鼠足部外伤部位的溃疡面积(P0.01);可极显著上调PDGF mRNA的表达(P0.01)。结论京万红软膏对大鼠缺血合并外伤型糖尿病足具有促进伤口愈合的功效,可能与上调PDGF mRNA的表达相关,但对VEGF及其受体Flt-1 mRNA的表达没有影响。

Improvement of Jingwanhong Ointment on diabetic foot with ischemia and trauma in rats by regulating the expression of PDGF mRNA

Objective To investigate the efficacy and mechanism of Jingwanhong Ointment on ischemic and traumatic diabetes foot in rats. Methods The diabetic rat model was reproduced. On this basis, the diabetic foot model of rats with ischemia and trauma was reproduced. Four groups were set up with 15 rats in each group, including sham operation group, model group, Jingwanhong Ointment group and recombinant human epidermal growth factor external solution (rhEGF) group. The changes of body weight, blood sugar, foot shape, and ulcer area were recorded before and after administration for 14 d. After administration, HE staining was performed on foot ulcer tissue. The effects of Jingwanhong Ointment on the expression of platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and its receptor FLT-1 were detected by RT-PCR. Results Jingwanhong Ointment had the effect of detumescence and muscle regeneration and wound healing in rats with ischemia and traumatic diabetic foot. Compared with the model group, Jingwanhong Ontment group could significantly reduce the ulcer area of foot injury in rats after 14 d of administration (P<0.01), and significantly up-regulate the expression of PDGF (P<0.01). Conclusion Jingwanhong Ointment can promote wound healing in rats with ischemia and traumatic diabetic foot. The mechanism may be related to the up-regulation of PDGF expression, but it has no effect on the expression of VEGF and Flt-1 receptor.